

Comparing the evidential strength for psychotropic drugs: a Bayesian meta-analysis

Merle-Marie Pittelkow¹ , Ymkje Anna de Vries^{2,3} , Rei Monden^{3,4} ,
Jojanneke A. Bastiaansen^{3,5}  and Don van Ravenzwaaij¹ 

Review Article

Cite this article: Pittelkow M-M, de Vries YA, Monden R, Bastiaansen JA, van Ravenzwaaij D (2021). Comparing the evidential strength for psychotropic drugs: a Bayesian meta-analysis. *Psychological Medicine* **51**, 2752–2761. <https://doi.org/10.1017/S0033291721003950>

Received: 8 April 2021

Revised: 6 September 2021

Accepted: 9 September 2021

First published online: 8 October 2021

Key words:

Bayesian meta-analysis; drug endorsement; evidential strength; psychotropic drugs

Author for correspondence:

Merle-Marie Pittelkow,

E-mail: m.pittelkow@rug.nl

¹Department Psychometrics and Statistics, University of Groningen, Groningen, the Netherlands; ²Department of Developmental Psychology, University of Groningen, Groningen, the Netherlands; ³Interdisciplinary Center Psychopathology and Emotion Regulation, Department of Psychiatry, University Medical Center Groningen, Groningen, the Netherlands; ⁴Department of Biomedical Statistics, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan and ⁵Department of Education and Research, Friesland Mental Health Care Services, Leeuwarden, the Netherlands

Abstract

Approval and prescription of psychotropic drugs should be informed by the strength of evidence for efficacy. Using a Bayesian framework, we examined (1) whether psychotropic drugs are supported by substantial evidence (at the time of approval by the Food and Drug Administration), and (2) whether there are systematic differences across drug groups. Data from short-term, placebo-controlled phase II/III clinical trials for 15 antipsychotics, 16 antidepressants for depression, nine antidepressants for anxiety, and 20 drugs for attention deficit hyperactivity disorder (ADHD) were extracted from FDA reviews. Bayesian model-averaged meta-analysis was performed and strength of evidence was quantified (i.e. BF_{BMA}). Strength of evidence and trialling varied between drugs. Median evidential strength was extreme for ADHD medication ($BF_{BMA} = 1820.4$), moderate for antipsychotics ($BF_{BMA} = 365.4$), and considerably lower and more frequently classified as weak or moderate for antidepressants for depression ($BF_{BMA} = 94.2$) and anxiety ($BF_{BMA} = 49.8$). Varying median effect sizes ($ES_{schizophrenia} = 0.45$, $ES_{depression} = 0.30$, $ES_{anxiety} = 0.37$, $ES_{ADHD} = 0.72$), sample sizes ($N_{schizophrenia} = 324$, $N_{depression} = 218$, $N_{anxiety} = 254$, $N_{ADHD} = 189.5$), and numbers of trials ($k_{schizophrenia} = 3$, $k_{depression} = 5.5$, $k_{anxiety} = 3$, $k_{ADHD} = 2$) might account for differences. Although most drugs were supported by strong evidence at the time of approval, some only had moderate or ambiguous evidence. These results show the need for more systematic quantification and classification of statistical evidence for psychotropic drugs. Evidential strength should be communicated transparently and clearly towards clinical decision makers.

Background

Psychiatric disorders can be treated with various psychotropic drugs. With a wide variety of drugs available, choosing the most appropriate one can be difficult, highlighting the importance of good evidence. Clinicians must be able to trust that there is strong evidence that the drug is effective. In the USA, drugs must be approved by the Food and Drug Administration (FDA) before they can be marketed. Although many aspects of a drug's profile must be considered in the approval process, the statistical evaluation of efficacy plays a central role. The FDA states that substantial evidence for efficacy is provided by 'at least two adequate and well-controlled studies, each convincing on their own' (U.S. Food and Drug Administration, 1998, p. 3). Occasionally, efficacy can also be established based on 'data from one adequate, well-controlled clinical investigation' (U.S. Food and Drug Administration, 1998, p. 3) or existing efficacy studies of closely related drugs, for example for modified-release variants of previously approved drugs (U.S. Food and Drug Administration, 1997, 1998; Wang et al., 2019).

In some cases, the current statistical evaluation process may lead to suboptimal decisions. The assumption that at least two independent randomised controlled trials (RCTs), or even fewer, provide substantial evidence of drug efficacy has been questioned (Monden et al., 2018). The FDA decision process does not systematically combine the information from positive (i.e. $p < 0.05$, rejecting the null hypothesis of no treatment effect) and negative (i.e. $p > 0.05$, not rejecting the null hypothesis) trials. As such, crucial information like the number of trials conducted before obtaining two positive trials is ignored (van Ravenzwaaij & Ioannidis, 2017, 2019). Instead, the Bayes factor (BF) has been suggested as a measure to quantify evidence holistically (Goodman, 1999; Monden et al., 2016, 2018). In contrast to p values, BFs quantify evidence in favour of both the null hypothesis (i.e. no treatment effect) and the alternative hypothesis (i.e. a treatment effect) by comparing the relative likelihood of the observed data under either hypothesis (Gronau, Ly, & Wagenmakers, 2019; Jeffreys, 1961;

© The Author(s), 2021. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

Rouder, Speckman, Sun, Morey, & Iverson, 2009; van Ravenzwaaij & Ioannidis, 2019). For instance, a BF_{10} (where the subscript indicates that the BF quantifies the likelihood of the alternative hypothesis relative to the null hypothesis) of 30 indicates the observed data are 30 times more likely to have occurred under the alternative hypothesis than under the null hypothesis (this is considered strong evidence for the alternative hypothesis; Jeffreys, 1961). Alternatively, a BF_{10} of 0.2 (or 1/5) indicates the observed data are five times more likely to have occurred under the null hypothesis than under the alternative hypothesis. Finally, a BF around 1 indicates equipoise (i.e. the data are about equally likely to have occurred under either hypothesis).

BFs may not only aid drug approval, but also drug prescription by clinicians. Besides effect sizes, which indicate the *magnitude* of the effect (Sullivan & Feinn, 2012), strength of evidence as quantified through BFs indicates how likely an effect (of any positive size) is to exist. Ideally, effect sizes should be clinically meaningful and the strength of evidence sufficiently large that the drug can be considered effective with relative certainty. There is a great body of literature regarding effect sizes of psychotropic drugs (Cipriani et al., 2018; Cortese et al., 2018; Huhn et al., 2019; Leucht, Helfer, Gartlehner, & Davis, 2015). However, little is known about the evidential strength of these drugs, which can differ despite homogeneous effect sizes. For example, in a previous study adopting a Bayesian framework, sertraline, fluoxetine, and desvenlafaxine had similar estimated effect sizes, but strength of evidence differed by a factor of two (Monden et al., 2018). Especially in situations such as these, BFs can offer an important additional source of information.

Evidential strength might differ between psychotropic drug groups as well as within. Previous research has shown that there are clear differences among psychotropic drug groups in terms of effect size (Leucht et al., 2015; Turner, Knoepflmacher, & Shapley, 2012). There are also indications that trial programmes differ between drug groups: for instance, drug approvals of antidepressants for anxiety disorders were generally supported by fewer trials than approvals of antidepressants for depression (Roest et al., 2015; Turner, Matthews, Linardatos, Tell, & Rosenthal, 2008). Although, to the best of our knowledge, there is no formal policy towards different standards for drug approval, these differences may lead to differences in the typical strength of evidence for different drug groups. However, little is known about the extent to which such factors influence the typical strength of evidence for different drug groups.

The present study

The goal of this study is to examine whether there are systematic differences in the strength of evidence for efficacy at the time of approval between different groups of psychotropic drugs. We consider four major classes: antidepressants approved for depression, antidepressants approved for anxiety disorders, antipsychotics for schizophrenia, and attention deficit hyperactivity disorder (ADHD) medication. We examine whether the current evaluation process generally leads to psychotropic drugs supported by substantial evidence (at the time of approval). To determine whether there are systematic differences across drug groups in terms of strength of evidence, we compare them across the disorder groups and investigate whether trial programme characteristics (e.g. effect sizes and sample sizes) are related to the strength of evidence per drug within each drug group.

Method

This study involved publicly available trial-level data. No ethical approval was needed.

Protocol and registration

Study information, details regarding prior knowledge of the data, and the analysis plan were preregistered at OSF before data analysis but after knowledge of the data. Deviations from the preregistration are reported in the online Supplementary material.

Data sources

Data sources were not identified by a systematic search. Instead, we obtained data for psychotropic drugs approved by the FDA. We used data extracted for previous meta-analyses, supplemented by data extracted by ourselves. Data on antidepressants for depression were obtained from Turner et al. (2008) and de Vries et al. (2018), on antidepressants for anxiety disorders from de Vries, de Jonge, Van Heuvel, Turner, and Roest (2016) and Roest et al. (2015), and on antipsychotics for schizophrenia from Turner et al. (2012). We extracted additional data on medications for ADHD, and antipsychotics for schizophrenia approved after publication of Turner et al. (2012) from FDA reviews. No additional data extraction was necessary for depression or anxiety disorders, as no new antidepressants were approved for these indications after previous publications. We followed data extraction procedures originally proposed by Turner et al. (2008) described in detail elsewhere (Turner et al., 2012). In short, for each drug we retrieved the corresponding FDA reviews from the FDA's website. Within the Drug Approval package, data relevant to the FDA's determination of drug efficacy were examined. Clinical phase II/III trials pivotal in the endorsement decision of the drug were eligible for inclusion, regardless of their outcome. Efficacy data were extracted preferably from the statistical review, and from the medical review or team leader memos, if necessary. In total, we included data for 15 antipsychotics ($N_{\text{trials}} = 43$, $n_{\text{treatment}} = 9937$, $n_{\text{control}} = 4303$), 16 antidepressants approved for depression ($N_{\text{trials}} = 105$, $n_{\text{treatment}} = 14\,042$, $n_{\text{control}} = 9917$), nine antidepressants approved for anxiety ($N_{\text{trials}} = 59$, $n_{\text{treatment}} = 8745$, $n_{\text{control}} = 6618$), and 20 drugs approved for ADHD ($N_{\text{trials}} = 46$, $n_{\text{treatment}} = 5705$, $n_{\text{control}} = 3508$).[†] For anxiety, we focused on generalised anxiety disorder (GAD), obsessive compulsive disorder (OCD), panic disorder (PD), post-traumatic stress disorder (PTSD), and social anxiety disorder (SAD). Some drugs were approved for multiple anxiety disorders. Consequently, we included 21 endorsement decisions for anxiety, resulting in a total of 72 drug-disorder combinations.

We included data for all available short-term, placebo-controlled, parallel-group, and cross-over phase II/III clinical trials. We excluded studies concerned with relapse or discontinuation of the medication, long-term extension trials, and studies without a placebo control group, as these do not qualify as 'well-controlled' trials (U.S. Food and Drug Administration, 2020). We excluded data on non-approved sub-therapeutic dosages (i.e. not effective dosages), as we were concerned with the evidence load regarding dosages associated with a therapeutic effect.

[†]The notes appear after the main text.

Statistical analysis

Analysis was conducted in R (4.0.1), using the ‘BayesFactor’ (0.9.12–4.2) (Morey, Rouder, Jamil, & Morey, 2015) and ‘metaBMA’ (Heck, Gronau, & Wagenmakers, 2017) packages.

Individual BF and effect size calculation

We calculated t statistics using sample size and p values. For parallel-group trials, we used independent samples t tests and for cross-over trials, we used paired samples t tests (Higgins et al., 2019). We used two-sided tests, in concordance with the FDA policy. Following Monden et al. (2018), we calculated a t statistic for all dose levels in fixed-dose trials with multiple drug arms, whereas one t value was calculated for flexible-dose trials with a single drug arm. When precise p values were unavailable, t statistics were calculated based on other information (e.g. mean differences) or imputed (see online Supplementary material). To determine the strength of evidence that an effect exists, we calculated Jeffreys–Zellner–Siow BF s (Rouder et al., 2009; van Ravenzwaaij & Etz, 2020). For each comparison, BF s were calculated using t statistics and sample size of the drug and placebo groups. We used a default Cauchy prior with location parameter zero and scale parameter $1/\sqrt{2}$ (Bayarri, Berger, Forte, & García-Donato, 2012; Consonni, Fouskakis, Liseo, & Ntzoufras, 2018). As the FDA follows two-sided tests with a check for direction, thus *de facto* performing a one-sided test, we truncated below zero, and calculated one-sided BF s (Senn, 2008).

To determine the size of an effect, we calculated the standardised mean difference (SMD). For parallel group trials, we calculated the corrected Hedges g . For cross-over trials, the uncorrected SMD was used.

Model-averaged Bayesian meta-analysis

We implemented Bayesian model-averaging (BMA; Gronau, Heck, Berkhout, Haaf, & Wagenmakers, 2021), as neither a fixed-effect model (assuming the same underlying ‘true’ effect-size) nor a random-effect model (being overly complex for meta-analysis of only a handful of trials) was believed to be necessarily best-suited for the present data. Instead, we weighted the results from both models according to their posterior probability, thus fully acknowledging the uncertainty with respect to the choice between a fixed or random-effect model (Gronau et al., 2017; Hinne, Gronau, van den Bergh, & Wagenmakers, 2020).

To conduct a Bayesian meta-analysis, prior distributions were assigned to the model parameters (Gronau et al., 2017). For the standardised effect size, we used a default, zero-centred Cauchy distribution with scale parameter equal to $1/\sqrt{2}$ (Morey et al., 2015). For the one-sided hypothesis test, we used the same distribution with values below zero truncated. For the between-study heterogeneity parameter τ in random-effect models, we used an informed prior distribution based on an analysis of 14 886 meta-analyses from the Cochrane Database of Systematic Reviews (Turner, Davey, Clarke, Thompson, & Higgins, 2012, 2015), namely a log normal distribution with mean $\mu = -2.12$ and standard deviation $s.d. = 1.532$. We performed one Bayesian meta-analysis per endorsement decision. This yielded pooled estimates of both effect size and strength of evidence for the effects (i.e. efficacy of a certain drug for a specific mental disorder), in the form of model-averaged BF s (BF_{BMA}). A total of 63 Bayesian meta-analyses were performed. For nine drug-disorder combinations supported by a single two-arm trial, we did not conduct a Bayesian meta-analysis, but used the individual BF

and effect size instead.² Hence, results are reported for 72 drug-disorder combinations.

The resulting BF_{BMA} were used to describe the proportion of well-supported endorsement decisions. We used different thresholds to quantify ‘substantial’ evidence. A BF_{10} between 1/3 and 3 is interpreted as ambiguous evidence, while a BF_{10} between 3 and 10 provides moderate, a BF_{10} between 10 and 30 strong, and a BF_{10} above 30 very strong evidence for the treatment effect (Jeffreys, 1961). Importantly, these thresholds are used for demonstrative purposes and we did not aim for just another hard threshold such as $p < 0.05$ (see Gelman, 2015).

Sensitivity analysis

To study the impact of the choices we made for the prior distributions on outcomes, we performed a sensitivity analysis by setting parameter estimates varied from $r = (1/6) \times \sqrt{2}$ to $r = (3/2) \times \sqrt{2}$. Additionally, we inspected the differences between fixed-effect and random-effect models and how excluding imputed values or cross-over trials impacted the results. Details can be found in the online Supplementary material.

Results

Proportion of studies supported by substantial evidence

Figures 1 and 2 visualise the results of the BMA meta-analyses for each of the disorder groups. Tables including detailed information for all analyses performed can be found in the online Supplementary material. Overall, three (4.2%) BF_{BMA} s indicated ambiguous evidence ($1/3 < BF_{BMA} < 3$): sertraline approved for PTSD ($BF_{BMA} = 0.7$), vilazodone ($BF_{BMA} = 0.5$), and bupropion approved for depression ($BF_{BMA} = 2.7$). Four (5.6%) meta-analytic BF_{BMA} s indicated only modest evidence for a treatment effect ($3 < BF_{BMA} < 10$): Daytrana for ADHD ($BF_{BMA} = 8.3$), sertraline approved for SAD ($BF_{BMA} = 7.3$), and paroxetine ($BF_{BMA} = 4.4$) and paroxetine CR ($BF_{BMA} = 4.4$) for PD. Ten (13.9%) BF_{BMA} s showed moderately strong evidence for treatment effects ($10 < BF_{BMA} < 30$), including five antidepressants approved for anxiety, two antidepressants for depression, two antipsychotics, and one ADHD medication. The majority of drugs (76.3%) were supported by strong pro-alternative evidence ($BF_{BMA} > 30$).

Differences in strength of evidence across disorders

Detailed results (i.e. meta-analytic BF s and pooled effect sizes, individual trial BF s and effect sizes, sample sizes, and number of trials) are presented in online Supplementary Table S1. Summary results are presented in Table 1. Because the distributions of BF s were heavily right-skewed, we report the median instead of the mean.

Although the median meta-analytic BF of each disorder group indicated ‘very strong evidence’, the strength of evidence differed between disorders. The highest median strength of evidence was found for ADHD ($BF_{BMA} = 1820.4$), followed by antipsychotics for schizophrenia ($BF_{BMA} = 365.4$). Median strength of evidence was lower for antidepressants for depression ($BF_{BMA} = 94.2$) and for anxiety ($BF_{BMA} = 49.8$). Similarly, variability in BF_{BMA} differed between disorders. The largest variance was found in ADHD ($8.3-2.3 \times 10^{15}$), followed by schizophrenia ($26.7-8.0 \times 10^5$). For antidepressants approved for depression ($0.8-3.3 \times 10^5$) and anxiety ($0.7-1.3 \times 10^5$), the range was the smallest.




Fig. 1. Model-averaged meta-analytic *BFs* and pooled effect estimates. Error bars represent 95% highest density interval. Note that the x- and y-axis has different dimensions for medication approved for ADHD. For some drug *BFs* and effect size correspond to a single trial (indicated by a Asterisk and dotted line depicting the 95% confidence intervals). Numbers are used to differentiate drugs with the same non-proprietary name (1 = Abilify, 2 = Aristada, 3 = Zyprexa, 4 = Zyprexa Relprev, 5 = Invega, 6 = Invega Sustenna, 7 = Risperdal, 8 = Perseris kit).

Individual *BFs* and trial characteristics

Median individual trial *BFs* are presented in online Supplementary Table S1 (for a visual representation, see online Supplementary Figs S1 through S4). Individual *BFs* differed (i.e. *BFs* corresponding to individual trials) between the four disorder groups. The median individual *BF* was the highest for ADHD ($BF = 185.0$), followed by antipsychotics ($BF = 21.0$) and anxiety ($BF = 6.8$). The median individual *BF* was the lowest for depression ($BF = 1.3$). Trial strength of evidence varied for all disorder groups (see Table 1).

The relationships between individual *BFs* and both effect size and sample size are shown in Fig. 3. The scatterplot of the effect sizes and individual *BFs* shows a positive association ($r_{\log(BF),ES} = 0.492$), whereas the scatterplot of sample sizes and individual *BFs* does not show a clear pattern (e.g. the highest *BF* for ADHD trials had the smallest sample size; $r_{\log(BF),N} = 0.056$), although this may be due to confounding with other factors (such as effect size).

We observed variation in sample size for trials concerning ADHD medication (20–563). This can be partially explained by the inclusion of cross-over trials, which by design have comparatively small sample sizes. Trials were generally randomised, controlled, parallel group trials (parallel-group RCTs); however, crossover trials were sometimes performed for drugs approved for the treatment of ADHD. Smaller sample sizes did not necessarily correspond to ambiguous evidence. For instance, two cross-over trials for ADHD indicated very strong pro-alternative evidence with small sample sizes ($n = 20$, $ES = 1.74$, $BF = 189.4$ and $n = 39$, $BF = 3.70 \times 10^{14}$). This was the case for parallel trials for depression and schizophrenia, as well ($n = 66$, $ES = 0.84$, $BF = 61.1$ and $n = 104$, $ES = 0.73$, $BF = 163.7$).

The lowest individual *BFs* were found for depression ($BF = 1.3$), which might be explained by the small effect sizes ($ES =$

0.27). As illustrated in Fig. 3a, antidepressants for depression commonly displayed the smallest effect sizes, corresponding to the smallest individual *BFs*. In contrast, antipsychotics and ADHD medication showed larger effect sizes ($ES = 0.44$ and $ES = 0.65$, respectively) corresponding to stronger evidential strength.

Meta-analytic *BFs* and trial characteristics

The very strong evidence obtained for most ADHD medications appeared to be primarily due to high individual *BFs*, as the number of trials for each ADHD drug was very small. In contrast, very strong evidence for depression was generally achieved through a large number of trials, despite small studies and very low individual *BFs*. Larger numbers of trials corresponded to a greater proportion of trials being deemed questionable or negative by the FDA. For example, for paroxetine for depression, 16 trials were mentioned, of which nine were deemed questionable or negative. Our Bayesian re-analysis suggested evidence for an additional trial to be ambiguous. Nonetheless, the meta-analytic *BF* suggested very strong pro-alternative evidence for the drug to treat depression ($BF_{BMA} = 10\,267.8$).

Under a Bayesian framework, more trials (i.e. more data) equal more evidence for the more probable hypothesis. In other words, with accumulating data the evidential strength (i.e. the *BF*) tends to point towards either zero (in case the null hypothesis is true) or infinity (in case the alternative hypothesis is true). However, we do not observe this relationship across drugs in practice ($r_{\log(BF), N_{trials}} = 0.146$ see Fig. 4). A likely explanation is that more trials are run for drugs with lower effect sizes to compensate. Trials concerning antidepressants approved for anxiety were slightly higher powered (i.e. had larger effect sizes and sample sizes)

Table 1. Overview of meta-analytic *BFs* (BF_{BMA}) and pooled effect sizes per drug (ES_{BMA}), individual trial *BFs* (*BF*) and effect sizes (*ES*), sample size for individual trials (N_i), and number of trials (N_{trials}) across the four disorder groups

		Schizophrenia	Depression	Anxiety	ADHD
BF_{BMA}	Median	365.4	94.2	49.8	1820.4
	Range (min-max)	$26.7-8.0 \times 10^5$	$0.8-3.3 \times 10^5$	$0.7-1.3 \times 10^5$	$8.3-2.3 \times 10^{15}$
ES_{BMA}	Median	0.45	0.30	0.37	0.72
	Range (min-max)	0.27-0.79	0.11-0.40	0.14-0.55	0.30-1.89
<i>BF</i>	Median	21.0	1.3	6.8	185.0
	Range (min-max)	$0.1-1.0 \times 10^9$	$0.1-7.5 \times 10^7$	$0.1-4.6 \times 10^{64}$	$0.2-1.4 \times 10^{19}$
<i>ES</i>	Median	0.44	0.27	0.38	0.65
	Range (min-max)	-0.13 to 0.92	-0.29 to 0.84	-0.15 to 1.15	0.04-1.89
N_i	Median	324	218	254	189.5
	Range (min-max)	68-636	29-704	87-565	20-563
N_{trials}	Median	3	5.5	3	2
	Range (min-max)	1-6	3-16	1-4	1-6




Fig. 3. Individual *BFs* on a log scale plotted against sample size (left) and effect size (right). Symbols and shading indicate the four different disorder groups.

Discussion

Even though approval of psychotropic drugs is based on the same guideline and processed through the same pathway and by the same group within the FDA, we detected large differences in

evidential strength and trial programmes. Although efficacy for the majority of psychotropic drugs was supported by very strong evidence at the time of approval, we observed substantial variation in the strength of evidence between approved psychotropic drugs:




Fig. 4. Model-averaged *BFs* on a log scale plotted against the number of performed trials. Symbols and shading indicate the four different disorder groups.

ADHD medication was supported by extreme evidence, whereas evidence for antidepressants for both depression and anxiety was considerably lower and more frequently classified as weak or moderate.

Differences in evidential strength might be partly explained by differences in trial programmes. For instance, ADHD drugs typically had very large effect sizes, resulting in extreme evidence for efficacy despite comparatively fewer and smaller trials. All else being equal, larger effect sizes correspond to larger *t* values, which in turn correspond to larger *BFs*. A potential drawback here is that the drug is tested on too few people to effectively gather evidence to rely on for safety. As most ADHD drugs are variants of methylphenidate, this may be considered acceptable. However, one might wonder: if a drug is considered different enough that a new approval application with new trials is needed to establish efficacy, is it reasonable to assume that safety will be the same?

In contrast, for depression in particular we saw clinical trial programmes with comparatively many trials and participants, meaning that there is much more experience with the drug at the time of approval. Evidence for efficacy, however, is considerably lower compared to ADHD and schizophrenia. The most likely explanation for this finding is that effect sizes for antidepressants were generally smaller than for other drug groups. Alternatively, heterogeneous samples for depression and anxiety, due to more ambiguous diagnostic criteria, might have contributed to larger between-study variation and thus lower evidential strength.

Using a Bayesian approach allowed us to identify cases in which psychotropic drugs were approved with moderate or even

ambiguous evidence for its efficacy. Approximately, a quarter of all meta-analytic *BFs* fell within this tier (i.e. $BF_{BMA} < 30$). In a few instances, drugs were approved despite ambiguous statistical evidence (i.e. $1/3 < BF_{BMA} < 3$). Sometimes approval was based on other considerations. For example, bupropion SR (sustained-release) was approved based on bio-equivalence with immediate-release bupropion, despite negative efficacy trials for bupropion SR (U.S. Food and Drug Administration ‘Bupropion SR’, 1996). Other times, negative or ‘failed’ trials were not included in the efficacy determination. For example, for vilazodone, three of five trials were considered ‘failed’, as the active comparator did not separate from placebo. The FDA has a history of ignoring failed trials because they supposedly lack assay sensitivity, the ability to differentiate an effective treatment from a less effective or ineffective one (Chuang-Stein, 2014). Although other considerations certainly play a role in the approval process, the example of vilazodone illustrates how the FDA’s current practice of determining efficacy using two independent statistically significant trials (regardless of the number of additional negative trials) can lead to inconsistent decision making in practice. Under the Bayesian framework, endorsement of this drug would not have been recommended.

How *BFs* could aid evidence-based treatment choices

For the purpose of drug development and endorsement, Bayesian meta-analysis offers several advantages over classical, frequentist meta-analysis, suggested by the FDA (U.S. Department of Health and Human Services et al., 2017). Although frequentist

meta-analysis is well-equipped to estimate the size of a treatment effect and its uncertainty (van Ravenzwaaij & Ioannidis, 2019), it cannot differentiate between the absence of evidence (uncertainty regarding the effect) and evidence of absence (e.g. evidence for effect = 0; a similar argument was made by Monden et al., 2018). This is especially important in the context of failed or negative trials, which could either indicate insufficient data or non-effectiveness of the drug. If the problem is merely the absence of evidence, the sponsor might perform additional trials to prove efficacy, whereas non-approval should be issued when evidence of absence has been demonstrated.

Bayesian meta-analysis yields *both* pooled effect sizes and evidential strength. Effect size estimates from the current analysis are similar to those from previous meta-analyses. Combining pre- and post-marketing studies, effect sizes for methylphenidate for ADHD, antipsychotics, and antidepressants approved for depression were estimated to be 0.77, 0.51, and 0.38, respectively (Leucht et al., 2015). These estimates are slightly larger than ours (i.e. 0.72, 0.45, and 0.30, respectively), which may be because we included unpublished, negative trials. Moreover, our effect size estimates are similar to previous network meta-analyses, which aimed to compare the efficacy and safety profiles between antipsychotics (Huhn et al., 2019), antidepressants for depression (Cipriani et al., 2018), and ADHD medication (Cortese et al., 2018). For example, estimates for antipsychotics ranged from 0.27 to 0.89 (Huhn et al., 2019; here: 0.27–0.79) and the pooled effect size for antidepressants was 0.30 (Cipriani et al., 2018; here: 0.30).

Our study adds novel information to previous research by using *BFs* to estimate the strength of evidence. The network meta-analyses conclude with rankings based on efficacy and safety data. We offer additional insight into the strength of evidence for efficacy. Sometimes, our rankings align, lending further support to the efficacy of the drug. For example, based on effect size, Huhn et al. (2019) ranked risperidone in the top tier and our analysis additionally indicates very strong support for the treatment effect. In other cases, *BFs* advise caution. For example, based on effect size, Huhn et al. (2019) ranked olanzapine highly, whereas our analysis places it in the lower quarter in comparison with the other drugs. Our analysis suggests that all else being equal, risperidone should be preferred over olanzapine. Additionally, *BFs* can help to refine rankings based on efficacy and safety data. For example, Cipriani et al. (2018) performed a network meta-analysis pooling efficacy and safety data for antidepressants for depression. Based on relatively high response rates and relatively low dropout rates, they recommended – among others – mirtazapine and paroxetine. Here, paroxetine is supported by extreme evidence, whereas mirtazapine has the third lowest evidential strength. All else being equal, paroxetine should be preferred over mirtazapine. For the purpose of drug prescription, *BFs* offer a valuable source of information for clinicians. Prescription and use of psychotropic drugs has steadily increased over the past few decades (Ilyas & Moncrieff, 2012; Olfson & Marcus, 2009; Stephenson, Karanges, & McGregor, 2013). With a wide variety of drugs available, choosing the most appropriate one can be difficult, highlighting the importance of good evidence. Next to safety and patient-specific concerns, considerations regarding effect size and evidential strength play a central role. Commonly, strength of evidence is assessed by qualitative or subjective criteria. The American Psychological Association (APA) considers evidential strength for their recommendations by reviewing the available literature and assessing risk of bias, the degree to which reported effects are unidirectional, directness of

the outcome measure, quality of the control condition, and precision of the estimate (e.g. width of a 95% confidence interval; American Psychological Association, 2019; American Psychological Association, 2017). Although these considerations are certainly meaningful, implementing them in clinical practice can be unsystematic, easily influenced by the rater, and might fail to effectively quantify strength of evidence (i.e. the likelihood of the treatment effect existing). For example, the APA recommends sertraline for the treatment of PTSD and argues that this decision is supported by the moderate strength of evidence. In contrast, our analysis suggests no evidence for a treatment effect of sertraline at the time of approval for PTSD.

Moreover, *BFs* offer a valuable source of information when effect sizes are highly comparable between drugs. For instance, the APA concludes that many antidepressants are equally effective (American Psychological Association, 2019) and makes no clear recommendation which one to prefer. In these cases, *BF* could be used as an additional criterion, as antidepressants vary substantially in evidential strength (see also Monden et al., 2018). For example, leaving aside non-efficacy considerations, but considering both the effect size and evidential strength, one might choose venlafaxine or paroxetine over sertraline or citalopram, two very commonly prescribed antidepressants (Moore & Mattison, 2017; although we acknowledge that safety/tolerability considerations may alter this choice). This advantage still holds if effect sizes vary from medium to large. For example, for ADHD drugs, Cotelpla XR, Evekeo ODT, and Adderall clearly demonstrated the highest evidential strength with comparable effect size and might be preferred over the others.

Strengths and limitations

Adopting a Bayesian framework enabled us to capture differences in evidential strength between disorders and drug groups. Nonetheless, the results should be considered in light of a few limitations. First, although we used information from the FDA-registered trials, limiting the influence of reporting bias, we were confined to data from approved drugs and pre-marketing studies. Consequently, we cannot speak to the process and statistical evidence of non-approval, or strength of evidence after post-marketing studies. As such, the current results only reflect the evidential strength at the time of approval but are not necessarily accurate reflections of the current state of evidence. Second, some values were unavailable and had to be imputed, which might have introduced extra noise. Nonetheless, imputation did not seem to be associated with increased between-study heterogeneity as indicated by comparable posterior probabilities of the random-effect model between drugs for which test statistics were available and drugs for which test statistics were imputed. Finally, Bayesian analysis is dependent on the choice of prior. Although this is an often-heard critique, we mostly restricted our analyses to default priors to ensure comparability of our results across drug groups. Furthermore, our sensitivity analysis indicated that different choices for the scale parameter of the prior did not change interpretation of the *BF* qualitatively in the present analysis.

The main strength of our study is that, to our knowledge, we have performed the first large-scale comparison of evidential strength between several disorders. Previously, Bayesian methods have been proposed for and discussed in the context of the drug development and endorsement (Burke, Billingham, Girling, & Riley, 2014; Cipriani et al., 2018; Huhn et al., 2019; Monden et al., 2016, 2018; van Ravenzwaaij & Ioannidis, 2019;

Woodcock, Temple, Midthun, Schultz, & Sundlof, 2005). In recent years, Bayesian network meta-analyses specifically became increasingly popular in medical sciences (Hamza et al., 2021; Holper, 2020; Huhn et al., 2019). Our study differs from previous studies that were concerned with efficacy and tolerability, but that either did not address evidential strength or did not compare evidential strength across different psychological disorders. Here, we provided an overview of the evidential standard for psychotropic drugs at the time of FDA approval and demonstrated how psychotropic drugs differ in their evidential strength, using *BFs*.

Conclusion

Taken together, the present analysis offers interesting insights into the evidential strength within and across different psychotropic drugs. We observed large differences in evidential strength and trialling between disorders. Although the majority of re-analysed drugs was supported by substantial evidence, we also observed cases where the current approval process led to endorsement despite ambiguous statistical evidence. Moreover, evidential strength differed greatly between drugs and across disorder groups. Lower evidential support for efficacy was observed more frequently for antidepressants. Differences in evidential strength might be a consequence of different standards in trialling. The *BF* as a measure of evidential strength might offer a valuable, additional source of information and helps to set up a consistent and transparent standard for evaluating strength of evidence of efficacy in the approval process of psychotropic drugs.

Supplementary material. The supplementary material for this article can be found at <https://doi.org/10.1017/S0033291721003950>.

Data. The datasets generated and analysed during the current study are available at OSF, <https://osf.io/364t5>.

Acknowledgements. We would like to acknowledge the Center for Information Technology of the University of Groningen for their support and for providing access to the Peregrine high performance computing cluster. Rei Monden was partially supported by the Clinical Investigator's Research Project in Osaka University Graduate School of Medicine.

Author contributions. Initial planning and preregistration were drafted by DvR, YAdV, and MMP, and RM and JAB provided feedback. YAdV and MMP collected the additional data. MMP performed data analysis and drafted the manuscript under supervision of DvR and YAdV. All co-authors provided detailed feedback. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Financial support. This project is funded by an NWO Vidi grant to D. van Ravenzwaaij (016.Vidi.188.001).

Conflict of interest. None.

Notes

1 For reporting of ADHD drugs, we use the commercial instead of the non-proprietary names as they are common variants of the same active agent.

2 That is, fluvoxamine CR approved for OCD, paroxetine CR approved for SAD, and seven drugs approved for the treatment of ADHD (i.e. Contempla XR, Daynavel XR, Evekeo ODT, Metadate CD, QuillChew, Quillivant, and Ritalin LA).

References

American Psychological Association (2017). *Clinical practice guideline for the treatment of posttraumatic stress disorder (PTSD) in adults*. Retrieved from <https://www.apa.org/ptsd-guideline/ptsd>.

- American Psychological Association (2019). *Clinical practice guideline for the treatment of depression across three age cohorts*. Retrieved from <https://www.apa.org/depression-guideline/guideline>.
- Bayarri, M. J., Berger, J. O., Forte, A., & García-Donato, G. (2012). Criteria for Bayesian model choice with application to variable selection. *Annals of Statistics*, 40(3), 1550–1577. doi: 10.1214/12-AOS1013
- Burke, D. L., Billingham, L. J., Girling, A. J., & Riley, R. D. (2014). Meta-analysis of randomized phase II trials to inform subsequent phase III decisions. *Trials*, 15(1), 346. doi: 10.1186/1745-6215-15-346
- Chuang-Stein, C. (2014). Assay sensitivity. *Encyclopedia of Statistical Sciences*, 1–5.
- Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., ... Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. *The Lancet*, 391(10128), 1357–1366. doi: 10.1016/S0140-6736(17)32802-7
- Consonni, G., Fouskakis, D., Liseo, B., & Ntzoufras, I. (2018). Prior distributions for objective Bayesian analysis. *Bayesian Analysis*, 13(2), 627–679. doi: 10.1214/18-BA1103
- Cortese, S., Adamo, N., Giovane, C. D., Mohr-Jensen, C., Hayes, A. J., Carucci, S., ... Cipriani, A. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. *The Lancet Psychiatry*, 5(9), 727–738. doi: 10.1016/S2215-0366(18)30269-4
- de Vries, Y. A., de Jonge, P., Van Heuvel, E. D., Turner, E. H., & Roest, A. M. (2016). Influence of baseline severity on antidepressant efficacy for anxiety disorders: Meta-analysis and meta-regression. *British Journal of Psychiatry*, 208(6), 515–521. doi: 10.1192/bjp.bp.115.173450
- de Vries, Y. A., Roest, A. M., De Jonge, P., Cuijpers, P., Munafò, M. R., & Bastiaansen, J. A. (2018). The cumulative effect of reporting and citation biases on the apparent efficacy of treatments: The case of depression. *Psychological Medicine*, 48(15), 2453–2455. doi: 10.1017/S0033291718001873
- Gelman, A. (2015). About a zillion people pointed me to yesterday's xkcd cartoon. Available at <https://statmodeling.stat.columbia.edu/2015/01/27/zillion-people-pointed-xkcd-cartoon/>.
- Goodman, S. N. (1999). Toward evidence-based medical statistics. 2: The Bayes factor. *Annals of Internal Medicine*, 130(12), 1005–1013. doi: 10.7326/0003-4819-130-12-199906150-00019
- Gronau, Q. F., Heck, D. W., Berkhout, S. W., Haaf, J. M., & Wagenmakers, E. J. (2021). A primer on Bayesian model-averaged meta-analysis. *Advances in Methods and Practices in Psychological Science*, 4(3). doi: 25152459211031256
- Gronau, Q. F., Ly, A., & Wagenmakers, E.-J. (2019). Informed Bayesian *t* tests. *The American Statistician*, 74(2), 1–14. doi: 10.1080/00031305.2018.1562983.
- Gronau, Q. F., Van Erp, S., Heck, D. W., Cesario, J., Jonas, K. J., & Wagenmakers, E.-J. (2017). A Bayesian model-averaged meta-analysis of the power pose effect with informed and default priors: The case of felt power. *Comprehensive Results in Social Psychology*, 2(1), 123–138.
- Hamza, T., Cipriani, A., Furukawa, T. A., Egger, M., Orsini, N., & Salanti, G. (2021). A Bayesian dose–response meta-analysis model: A simulations study and application. *Statistical Methods in Medical Research*, 30(5), 1358–1372. doi: 10.1177/0962280220982643
- Heck, D. W., Gronau, Q. F., & Wagenmakers, E. J. (2017). MetaBMA: Bayesian model averaging for random and fixed effects meta-analysis. Available at <https://cran.r-project.org/web/packages/metaBMA/metaBMA.pdf>.
- Higgins, J., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M., ... Welch, V. (Eds.). (2019). *Cochrane handbook for systematic reviews of interventions* (2nd ed.). Chichester (UK): John Wiley & Sons.
- Hinne, M., Gronau, Q. F., van den Bergh, D., & Wagenmakers, E.-J. (2020). A conceptual introduction to Bayesian model averaging. *Advances in Methods and Practices in Psychological Science*, 3(2), 200–215. doi: 10.1177/2515245919898657
- Holper, L. (2020). Optimal doses of antidepressants in dependence on age: Combined covariate actions in Bayesian network meta-analysis. *EclinicalMedicine*, 18. doi: 10.1016/j.eclinm.2019.11.012
- Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., ... Leucht, S. (2019). Comparative efficacy and tolerability of 32

- oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. *The Lancet*, 394(10202), 939–951. doi: 10.1016/S0140-6736(19)31135-3
- Ilyas, S., & Moncrieff, J. (2012). Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010. *The British Journal of Psychiatry*, 200(5), 393–398. doi: 10.1192/bjp.bp.111.104257
- Jeffreys, H. (1961). *Theory of probability*. Oxford: Oxford University Press.
- Leucht, S., Helfer, B., Gartlehner, G., & Davis, J. M. (2015). How effective are common medications: A perspective based on meta-analyses of major drugs. *BMC Medicine*, 13(1), 1–5. doi: 10.1186/s12916-015-0494-1
- Monden, R., de Vos, S., Morey, R., Wagenmakers, E.-J., de Jonge, P., & Roest, A. M. (2016). Toward evidence-based medical statistics: A Bayesian analysis of double-blind placebo-controlled antidepressant trials in the treatment of anxiety disorders. *International Journal of Methods in Psychiatric Research*, 25(4), 299–308. doi: 10.1002/mpr.1507
- Monden, R., Roest, A. M., van Ravenzwaaij, D., Wagenmakers, E.-J., Morey, R., Wardenaar, K. J., & de Jonge, P. (2018). The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews. *Journal of Affective Disorders*, 235, 393–398. doi: 10.1016/j.jad.2018.04.040
- Moore, T. J., & Mattison, D. R. (2017). Adult utilization of psychiatric drugs and differences by sex, age, and race. *JAMA Internal Medicine*, 177(2), 274. doi: 10.1001/jamainternmed.2016.7507
- Morey, R. D., Rouder, J. N., Jamil, T., & Morey, M. R. D. (2015). Package ‘BayesFactor’. Available at <https://cran.r-project.org/web/packages/BayesFactor/BayesFactor.pdf>.
- Olfson, M., & Marcus, S. C. (2009). National patterns in antidepressant medication treatment. *Archives of General Psychiatry*, 66(8), 848–856. doi: 10.1001/archgenpsychiatry.2009.81
- Roest, A. M., De Jonge, P., Williams, C. D., de Vries, Y. A., Schoevers, R. A., & Turner, E. H. (2015). Reporting bias in clinical trials investigating the efficacy of second-generation antidepressants in the treatment of anxiety disorders: A report of 2 meta-analyses. *JAMA Psychiatry*, 72(5), 500–510. doi: 10.1001/jamapsychiatry.2015.15
- Rouder, J. N., Speckman, P. L., Sun, D., Morey, R. D., & Iverson, G. (2009). Bayesian *t* tests for accepting and rejecting the null hypothesis. *Psychonomic Bulletin and Review*, 16(2), 225–237. doi: 10.3758/PBR.16.2.225
- Senn, S. S. (2008). *Statistical issues in drug development*. Chichester, UK: John Wiley & Sons.
- Stephenson, C. P., Karanges, E., & McGregor, I. S. (2013). Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. *Australian & New Zealand Journal of Psychiatry*, 47(1), 74–87. doi: 10.1177/0004867412466595
- Sullivan, G. M., & Feinn, R. (2012). Using effect size – Or why the *p* value is not enough. *Journal of Graduate Medical Education*, 4(3), 279–282. doi: 10.4300/JGME-D-12-00156.1
- Turner, E. H., Knoepflmacher, D., & Shapley, L. (2012). Publication bias in antipsychotic trials: An analysis of efficacy comparing the published literature to the US food and drug administration database. *PLoS Medicine*, 9(3). doi: 10.1371/journal.pmed.1001189
- Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. *New England Journal of Medicine*, 358(3), 252–260. doi: 10.1056/NEJMsa065779
- Turner, R. M., Davey, J., Clarke, M. J., Thompson, S. G., & Higgins, J. P. (2012). Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. *International Journal of Epidemiology*, 41, 818–827. doi: 10.1093/ije/dys041
- Turner, R. M., Jackson, D., Wei, Y., Thompson, S. G., & Higgins, J. P. T. (2015). Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis. *Statistics in Medicine*, 34(6), 984–998. doi: 10.1002/sim.6381
- U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Research Center for Drug Evaluation, & Research Center for Biologics Evaluation (2017). M4E(R2): The CTD – Efficacy Guidance for Industry.
- U.S. Food and Drug Administration (1997). Guidance for Industry SUPAC-MR: Modified Release Solid Oral Dosage Forms. Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supac-mr-modified-release-solid-oral-dosage-forms-scale-and-postapproval-changes-chemistry>.
- U.S. Food and Drug Administration (1998). Guidance for Industry: E9 Statistical Principles for Clinical Trials. Available at <https://www.fda.gov/media/71336/download>.
- U.S. Food and Drug Administration (2020). CFR – Code of Federal Regulations Title 21. Available at <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/>.
- U.S. Food and Drug Administration ‘Bupropion SR’. (1996). FDA Drug Approval Documents. Paper 21. Available at <http://digitalcommons.ohsu.edu/fdadrug/21>.
- van Ravenzwaaij, D., & Etz, A. (2020). Simulation studies as a tool to understand Bayes factors. *Simulation*, 1, 0–385.
- van Ravenzwaaij, D., & Ioannidis, J. P. A. (2017). A simulation study of the strength of evidence in the recommendation of medications based on two trials with statistically significant results. *PLoS ONE*, 12(3). doi: 10.1371/journal.pone.0173184
- van Ravenzwaaij, D., & Ioannidis, J. P. A. (2019). True and false positive rates for different criteria of evaluating statistical evidence from clinical trials. *BMC Medical Research Methodology*, 19(1), 218–218. doi: 10.1186/s12874-019-0865-y
- Wang, Y. L., Chang, Y. T., Yang, S. Y., Chang, Y. W., Kuan, M. H., Tu, C. L., Hong, H. C., ... Hsu, L. F. (2019). Approval of modified-release products by FDA without clinical efficacy/safety studies: A retrospective survey from 2008 to 2017. *Regulatory Toxicology and Pharmacology*, 103, 174–180. doi: 10.1016/j.yrtph.2019.01.037
- Woodcock, J., Temple, R., Midthun, K., Schultz, D., & Sundlof, S. (2005). FDA senior management perspectives. *Clinical Trials: Journal of the Society for Clinical Trials*, 2(4), 373–378. doi: 10.1191/1740774505cn109oa